Stock Events

Stock Events

Pharming Group N.V. 

€10.80
435
+€0.20+1.89%Wednesday 07:01

Statistics

Day High
10.8
Day Low
10.8
52W High
17.5
52W Low
8.8
Volume
0
Avg. Volume
0
Mkt Cap
764.4M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 27Expected
Q1 2026
Q2 2026
Q3 2026
-0.01
0.01
0.02
0.03
Expected EPS
0.0188685
Actual EPS
0.026954999999999996

Financials

0.33%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
325.82MRevenue
1.09MNet Income

Analyst Ratings

$29.59Average Price Target
The highest estimate is ⁦31.11⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHG.MU. It's not an investment recommendation.
ING Groep N.V.
62
INGA.AS
Shell
61
SHELL.AS
Realty Income
53
O
ASML NV
52
ASML.AS

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Carlisle Companies
CSL
Mkt Cap14.54B
CSL Behring competes in the plasma-derived and recombinant therapeutic products space, similar to Pharming's focus on protein replacement therapies.
Takeda Pharmaceutical
TAK
Mkt Cap66.81B
Takeda Pharmaceutical Company has a strong presence in the rare diseases market, directly competing with Pharming's portfolio.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing with Pharming's approach to treatment.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals engages in the treatment of cystic fibrosis and other rare diseases, presenting competition in the rare disease market.
AMGEN
AMGN
Mkt Cap251.94B
Amgen operates in the biotechnology field focusing on rare diseases among other areas, making it a competitor in the biopharmaceutical market.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is involved in developing and marketing products for rare diseases, among other areas, competing with Pharming.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline has a diverse portfolio including treatments for rare diseases, competing with Pharming in various therapeutic areas.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the pharmaceutical and biotech industry.
Sanofi
SNY
Mkt Cap106.24B
Sanofi focuses on rare diseases, multiple sclerosis, and oncology, among others, competing with Pharming in the rare disease space.

About

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Show More
CEO
Kenneth Lynard
Employees
409
Country
Netherlands
ISIN
US71716E1055
WKN
000A2QLQY

Listings

F
DE
PHG.F
STU
DE
PHG.STU
XETRA
DE
PHGN.XETRA
STU
DE
PHGN.STU

0 Comments

Share your thoughts

FAQs

What is Pharming Group N.V. stock price today?▼
The current price of PHG.MU is €10.80 EUR — it has increased by +1.89% in the past 24 hours. Watch Pharming Group N.V. stock price performance more closely on the chart.
What is Pharming Group N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Pharming Group N.V. stocks are traded under the ticker PHG.MU.
Is Pharming Group N.V. stock price growing?▼
PHG.MU stock has risen by +3.85% compared to the previous week, the month change is a +17.39% rise, over the last year Pharming Group N.V. has showed a -18.18% decrease.
What is Pharming Group N.V. market cap?▼
Today Pharming Group N.V. has the market capitalization of 764.4M
When is the next Pharming Group N.V. earnings date?▼
Pharming Group N.V. is going to release the next earnings report on March 18, 2027.
What were Pharming Group N.V. earnings last quarter?▼
PHG.MU earnings for the last quarter are 0.03 EUR per share, whereas the estimation was 0.02 EUR resulting in a +42.86% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Pharming Group N.V. revenue for the last year?▼
Pharming Group N.V. revenue for the last year amounts to 325.82M EUR.
What is Pharming Group N.V. net income for the last year?▼
PHG.MU net income for the last year is 1.09M EUR.
How many employees does Pharming Group N.V. have?▼
As of November 7, 2026, the company has 409 employees.
In which sector is Pharming Group N.V. located?▼
Pharming Group N.V. operates in the Health & Wellness sector.
When did Pharming Group N.V. complete a stock split?▼
The last stock split for Pharming Group N.V. was on October 15, 2013 with a ratio of 1:1000.
Where is Pharming Group N.V. headquartered?▼
Pharming Group N.V. is headquartered in Leiden, Netherlands.